Paper Details

  1. Home
  2. Paper Details

A double-masked comparison of betaxolol and dipivefrin for the treatment of increased intraocular pressure.

Author: AlbrachtD C, CruzA M, KelleyE P, LampingK A, LeBlancR P, SiegelL I, SternK L, StoeckerJ F

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Betaxolol (0.5%), a cardioselective beta-adrenoceptor antagonist, and dipivefrin (0.1%), an alpha/beta-adrenergic agonist, were equally effective in reducing intraocular pressure. Both treatments caused similar minor heart rate increases, but betaxolol caused significantly more stinging or burning.
Paper Details　
Original Abstract of the Article :
Noncardioselective beta-adrenoceptor antagonists are used for treatment of increased intraocular pressure. Because these agents may be absorbed systemically, their use is of concern in patients with restricted pulmonary function. We compared the efficacy of betaxolol, a cardioselective beta-adrenoce...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0002-9394(14)71348-0

データ提供：米国国立医学図書館（NLM）

Beta-Blockers vs. Alpha/Beta-Adrenergic Agonists: Navigating the Desert of Ocular Hypertension

Ocular hypertension, a condition that increases pressure within the eye, can be a challenging desert to navigate. This study compares the effectiveness of betaxolol, a cardioselective beta-adrenoceptor antagonist, and dipivefrin, an alpha/beta-adrenergic agonist, in treating ocular hypertension. The researchers conducted a double-masked comparison trial to determine the efficacy and safety of both medications.

Beta-Blockers and Alpha/Beta-Adrenergic Agonists: Similar Efficacy

The study found that both betaxolol and dipivefrin were effective in reducing intraocular pressure, with similar reductions in mean pressure observed in both groups. However, betaxolol was associated with significantly more stinging or burning sensation compared to dipivefrin.

A Camel's Perspective: Choosing the Right Path

The desert of ocular hypertension can be challenging, and choosing the right treatment path is essential for managing this condition. This study suggests that both betaxolol and dipivefrin are effective treatment options, but individual preferences and potential side effects should be considered when making a decision.

Dr. Camel's Conclusion

This research provides valuable insights into the effectiveness of both betaxolol and dipivefrin in treating ocular hypertension. While both medications showed comparable efficacy, the study highlighted the importance of considering individual preferences and potential side effects when making treatment choices. Remember, navigating the desert of ocular hypertension is a journey best undertaken with the guidance of a healthcare professional.

Date :
  1. Date Completed 1993-09-23
  2. Date Revised 2019-06-27
Further Info :

Pubmed ID

8357055

DOI: Digital Object Identifier

10.1016/s0002-9394(14)71348-0

Related Literature

Article Analysis
・Effects of dipivefrin ophthalmic
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.